GoAI
Get started
Pulsenmore Ltd. Ordinary Shares logo

Pulsenmore Ltd. Ordinary Shares

PLSM

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$2.94

−$0.02 · -0.68%

Aug 21, 4:00 PM ET

PLSM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

26

Weakening

Sentiment

52

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pulsenmore Ltd. specializes in delivering self-scanning ultrasound technology for distant medical diagnosis and health screening throughout Israel and Europe. Its primary offering is the Pulsenmore at-home ultrasound system, which consists of a portable ultrasound unit that attaches to a patient's smartphone. An accompanying mobile application then securely uploads diagnostic images to the cloud for review. Furthermore, a specialized clinician dashboard enables medical professionals to examine stored video recordings or provide real-time guidance during a scan. Founded in 2014, the company is headquartered in Omer, Israel.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
IL
CEO
Elazar Sonnenschein
Listed since
Jan 21, 2026
Employees
71

Market position

Day range

Current $2.94

52-week range

Current $2.94

Open
$2.99
Previous close
$2.96
Volume
36.73K
0.03× average
Average volume
1.43M
Average daily volume
Market cap
19.12M USD
Beta
0.38
Market reference 1
50-day average
$3.8375
-23.39% below average
200-day average
$4.2326
-30.54% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
130.02M ILS
P/E (TTM)
-1.76×
P/B (TTM)
0.68×
P/S (TTM)
1.33×
EV / EBITDA
-10.21×
Earnings yield
-10.56%
Free cash flow yield
-22.00%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
81.03%
Operating margin
-62.13%
Net margin
-74.89%
Return on equity
-19.08%
Return on assets
-15.57%
Return on invested capital
-13.00%

Financial health

Debt / equity
0.02×
Current ratio
7.88×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends255%-428%-1111%-1795%Gross margin, FY2021: 13.12%Gross margin, FY2022: 36.55%Gross margin, FY2023: 0.65%Gross margin, FY2024: 21.43%Gross margin, FY2025: 84.15%Operating margin, FY2021: -1390.24%Operating margin, FY2022: -427.24%Operating margin, FY2023: -898.29%Operating margin, FY2024: -436.96%Operating margin, FY2025: -30.39%Net margin, FY2021: -1623.89%Net margin, FY2022: -204.54%Net margin, FY2023: -946.46%Net margin, FY2024: -380.25%Net margin, FY2025: -39.61%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 13.12%. Gross margin FY2022 36.55%. Gross margin FY2023 0.65%. Gross margin FY2024 21.43%. Gross margin FY2025 84.15%. Operating margin FY2021 -1390.24%. Operating margin FY2022 -427.24%. Operating margin FY2023 -898.29%. Operating margin FY2024 -436.96%. Operating margin FY2025 -30.39%. Net margin FY2021 -1623.89%. Net margin FY2022 -204.54%. Net margin FY2023 -946.46%. Net margin FY2024 -380.25%. Net margin FY2025 -39.61%.

Income trends

Revenue

40.02M ILS+315.22%

Operating income

−12.16M ILS+71.12%

Net income

−15.85M ILS+56.75%
Income trends across reported periods49.83M ILS10.6M ILS−28.64M ILS−67.88M ILSRevenue, FY2021: 1.58M ILSRevenue, FY2022: 10.59M ILSRevenue, FY2023: 6.14M ILSRevenue, FY2024: 9.64M ILSRevenue, FY2025: 40.02M ILSOperating income, FY2021: −21.92M ILSOperating income, FY2022: −45.25M ILSOperating income, FY2023: −55.11M ILSOperating income, FY2024: −42.12M ILSOperating income, FY2025: −12.16M ILSNet income, FY2021: −25.61M ILSNet income, FY2022: −21.66M ILSNet income, FY2023: −58.07M ILSNet income, FY2024: −36.65M ILSNet income, FY2025: −15.85M ILSFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.58M ILS. Revenue FY2022 10.59M ILS. Revenue FY2023 6.14M ILS. Revenue FY2024 9.64M ILS. Revenue FY2025 40.02M ILS. Operating income FY2021 −21.92M ILS. Operating income FY2022 −45.25M ILS. Operating income FY2023 −55.11M ILS. Operating income FY2024 −42.12M ILS. Operating income FY2025 −12.16M ILS. Net income FY2021 −25.61M ILS. Net income FY2022 −21.66M ILS. Net income FY2023 −58.07M ILS. Net income FY2024 −36.65M ILS. Net income FY2025 −15.85M ILS.
Metric (ILS)FY2025FY2024FY2023FY2022FY2021
Revenue40.02M ILS9.64M ILS6.14M ILS10.59M ILS1.58M ILS
Cost of goods sold6.34M ILS7.57M ILS6.1M ILS6.72M ILS1.37M ILS
Gross profit33.68M ILS2.07M ILS39.66K ILS3.87M ILS206.84K ILS
Research and development17.35M ILS18.87M ILS30.07M ILS28.28M ILS10.61M ILS
Selling, general, and administrative10.61M ILS33.99M ILS32.61M ILS29.32M ILS16.28M ILS
Operating expenses45.85M ILS44.18M ILS55.15M ILS49.12M ILS22.13M ILS
Interest income3.54M ILS5.31M ILS6.79M ILS3.03M ILS75.94K ILS
Interest expense315K ILS538.78K ILS605.78K ILS341.83K ILS288.78K ILS
Depreciation and amortization2.8M ILS2.85M ILS2.38M ILS1.27M ILS559.58K ILS
Operating income−12.16M ILS−42.12M ILS−55.11M ILS−45.25M ILS−21.92M ILS
Net income−15.85M ILS−36.65M ILS−58.07M ILS−21.66M ILS−25.61M ILS

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-2.47
FY2025
Latest fiscal-year revenue
40.02M ILS
FY2025 · +315.22% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-1.81-4.45-7.09-9.73FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend43.87M28.49M13.11M-2.27MFY21FY22FY23FY24FY25

PLSM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research PLSM

research.disclaimer